TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36351926

Group type: EXPERIMENTAL
Intervention: 5 g of CaCO3
Number of subjects: 2

Group type: COMPARATOR
Intervention: 0 g of CaCO3
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 10 g of CaCO3
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 15 g of CaCO3
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 20 g of CaCO3
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Genotype I
Number of subjects: 2

Group type: COMPARATOR
Intervention: Genotype II
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Genotype I and 5 g of CaCO3
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Correlation with stalk height
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Correlation with stalk diameter
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Correlation with number of mushroom branches
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Correlation with number of productive bags
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Correlation with number of fruits
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Correlation with fruit weight
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Correlation with dry weight
Number of subjects: 2
Study: 33271534

Group type: EXPERIMENTAL
Intervention: Plasma magnesium concentrations in quartile 1 (<0.76 mmol/L)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Plasma magnesium concentrations in quartile 4 (≥0.89 mmol/L)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Plasma magnesium concentrations in quartile 3 (0.83 to <0.89 mmol/L)
Number of subjects: 456
Study: 36226464

Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 2338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2338

Group type: EXPERIMENTAL
Intervention: Erenumab (responders)
Number of subjects: 2338

Group type: COMPARATOR
Intervention: Placebo (responders)
Number of subjects: 2338
Study: 33961212

Group type: EXPERIMENTAL
Intervention: Contextual cohort
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 35212645

Group type: EXPERIMENTAL
Intervention: Yoga and meditation for 60 minutes two times a week for 10 weeks, including during labor.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine midwifery care during labor (Control group).
Number of subjects: 90
Study: 32833845

Group type: EXPERIMENTAL
Intervention: Nonprogressive KCN group (serum vitamin D levels: 12.77 ± 5.52 ng/mL)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Progressive KCN group (serum vitamin D levels: 11.78 ± 4.32 ng/mL)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (serum vitamin D levels: 17.40 ± 5.12 ng/mL)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All groups (serum vitamin B12, FA, and Ca levels)
Number of subjects: 55
Study: 36214945

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (exact dosage and duration not specified)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 187
Study: 34389017

Group type: EXPERIMENTAL
Intervention: Step-Dep (stepped care program)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 236
Study: 35100035

Group type: EXPERIMENTAL
Intervention: Citrus depressa Hayata fruit extract (CFEx)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32089107

Group type: EXPERIMENTAL
Intervention: Intended but failed to apologize
Number of subjects: 284

Group type: COMPARATOR
Intervention: Refused to apologize or whose apologies were rejected
Number of subjects: 284
Study: 33143931

Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy
Number of subjects: 401

Group type: COMPARATOR
Intervention: Restrictive normovolemic therapy
Number of subjects: 401
Study: 32312645

Group type: EXPERIMENTAL
Intervention: Cemented femoral and tibial implants
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cemented tibial implant, uncemented femoral implant (hybrid group)
Number of subjects: 130
Study: 34494090

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 139242

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 139242
Study: 34159934

Group type: EXPERIMENTAL
Intervention: EPEA using Bio-Well 2.0
Number of subjects: 114
Study: 35894983

Group type: EXPERIMENTAL
Intervention: Cycle ergometer intervention during 3 lessons per week at self-selected intensity
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study: 34763594

Group type: EXPERIMENTAL
Intervention: SonoVue and oxytocin (group A)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Oxytocin (group B)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: SonoVue (group C)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control (group D)
Number of subjects: 330
Study: 36052473

Group type: EXPERIMENTAL
Intervention: 3-components phytotherapic composed of Herniaria hirsuta and Peumus boldus plus water oral intake for 12 days/month over 3 months (Group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No adjuvant phytotherapy (Group B)
Number of subjects: 34
Study: 33851854

Group type: EXPERIMENTAL
Intervention: Perceived financial barriers to screening
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Screening appointment costs
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Follow-up/future treatment costs
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Lost pay due to time missed from work
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Transportation costs
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Perceived out-of-pocket cost of screening
Number of subjects: 702
Study: 35365598

Group type: EXPERIMENTAL
Intervention: Ixazomib, cyclophosphamide, and dexamethasone (ICD)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cyclophosphamide and dexamethasone (CD)
Number of subjects: 112
Study: 34507244

Group type: EXPERIMENTAL
Intervention: Initial combination therapy (fluoropyrimidine, bevacizumab, irinotecan)
Number of subjects: 421
Study: 32093741

Group type: EXPERIMENTAL
Intervention: Lactocare (ZistTakhmir) capsules 500 mg every 12 hours for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo capsule containing only sterile maize starch, similar to synbiotic capsules for 14 days
Number of subjects: 40
Study: 32619656

Group type: COMPARATOR
Intervention: Endoscopic debridement alone (n=19)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Endoscopic debridement with intraoperative PRP application (n=17)
Number of subjects: 36
Study: 34181510

Group type: EXPERIMENTAL
Intervention: M18 (maize stored for 18 months)
Number of subjects: 270

Group type: COMPARATOR
Intervention: M0 (maize stored for 24 days)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: M36 (maize stored for 36 months)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: M18
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: M36
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: M0 and M36
Number of subjects: 270

Group type: COMPARATOR
Intervention: M0
Number of subjects: 270
Study: 32316886

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for insomnia (one group session of sleep hygiene education and four individual sessions of counseling)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study: 32978842

Group type: EXPERIMENTAL
Intervention: Novel antibiotic-free film-forming silicone-based wound dressing
Number of subjects: 231

Group type: COMPARATOR
Intervention: Topical triple antibiotic petrolatum-based ointment
Number of subjects: 231
Study: 33284129

Group type: EXPERIMENTAL
Intervention: SMS text messaging and health education
Number of subjects: 420

Group type: COMPARATOR
Intervention: Health education only (Control)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 420
Study: 35069809

Group type: EXPERIMENTAL
Intervention: Wearable transcutaneous electrical nerve stimulation (W‐TENS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Weak opioids (WO)
Number of subjects: 110
Study: 33357512

Group type: EXPERIMENTAL
Intervention: Riluzole (50 mg twice a day for 14 days before surgery and then for 28 days after surgery)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 290
Study: 35030242

Group type: EXPERIMENTAL
Intervention: Active implicit priming (IP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control implicit priming (IP)
Number of subjects: 41
Study: 33971855

Group type: EXPERIMENTAL
Intervention: Simplified guidance (3-page version)
Number of subjects: 1845

Group type: EXPERIMENTAL
Intervention: Simplified guidance with visual aids (3-page version with pictograms)
Number of subjects: 1845

Group type: COMPARATOR
Intervention: Control (7-page standard guidelines)
Number of subjects: 1845
Study: 35321888

Group type: COMPARATOR
Intervention: Completion surgery followed by an additional five cycles of chemotherapy (control arm)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: An additional three cycles of neoadjuvant chemotherapy followed by completion surgery and then two additional cycles of chemotherapy (experimental arm)
Number of subjects: 210
Study: 33683608

Group type: EXPERIMENTAL
Intervention: Humanoid robot-based distraction
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86
Study: 32927371

Group type: EXPERIMENTAL
Intervention: Prolonged exposure treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-exposure based treatment
Number of subjects: 31
Study: 35769481

Group type: EXPERIMENTAL
Intervention: WASH intervention (n = 33)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Stunted children (n = 44)
Number of subjects: 113

Group type: COMPARATOR
Intervention: IYCF (n = 55)
Number of subjects: 113
Study: 33657450

Group type: EXPERIMENTAL
Intervention: SSRI treatment (10mg escitalopram)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 66
Study: 35905798

Group type: EXPERIMENTAL
Intervention: Baduanjin (BDJ) exercise for 24 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Yoga exercise for 24 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (usual activity)
Number of subjects: 80
Study: 34510501

Group type: EXPERIMENTAL
Intervention: Average Treatment Effect (ATE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average Treated Effect in the Treated (ATT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overlap Weights
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matching Weights
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Entropy Weights
Number of subjects: 0
Study: 33167109

Group type: EXPERIMENTAL
Intervention: rSO2 guides controlled hypotension (group A)
Number of subjects: 120
Study: 35720011

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (transcutaneous electrical stimulation at nonacupoint position)
Number of subjects: 91
Study: 35367733

Group type: EXPERIMENTAL
Intervention: Bone marrow derived stem cells (BMSCs)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 34190947

Group type: EXPERIMENTAL
Intervention: Therapeutic communication application (IG group, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional class (CG group, n=30)
Number of subjects: 60
Study: 32938496

Group type: EXPERIMENTAL
Intervention: Sarilumab + methylprednisolone plus standard of care (SOC) for COVID-19
Number of subjects: 200

Group type: COMPARATOR
Intervention: Methylprednisolone plus standard of care (SOC) for COVID-19
Number of subjects: 200
Study: 34227392

Group type: EXPERIMENTAL
Intervention: PCI with drug-eluting stents
Number of subjects: 600

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 600
Study: 33075612

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 19229

Group type: EXPERIMENTAL
Intervention: Habitual Sleep Deprivation
Number of subjects: 19229

Group type: EXPERIMENTAL
Intervention: Weekday Sleep Deprivation
Number of subjects: 19229

Group type: EXPERIMENTAL
Intervention: Weekend Sleep Deprivation
Number of subjects: 19229

Group type: COMPARATOR
Intervention: Sleepwalking
Number of subjects: 19229
Study: 36398978

Group type: EXPERIMENTAL
Intervention: Approach-oriented coping
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Avoidant coping
Number of subjects: 170
Study: 32536331

Group type: EXPERIMENTAL
Intervention: 1.0 mg lorazepam
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 35151504

Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg)
Number of subjects: 964

Group type: COMPARATOR
Intervention: Bupropion (150 mg)
Number of subjects: 964
Study: 34278042

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day orally for 90 days
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 35076090

Group type: EXPERIMENTAL
Intervention: galcanezumab 120 mg
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: galcanezumab 240 mg
Number of subjects: 2680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2680
Study: 33601121

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (2000 IU/d)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU/d)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Combination of Vitamin A (2000 IU/d) and Vitamin D (400 IU/d)
Number of subjects: 753

Group type: COMPARATOR
Intervention: Control group (tuberculosis treatment only)
Number of subjects: 753
Study: 33356728

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (Strattice™)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Synthetic mesh (Prolene®)
Number of subjects: 29
Study: 36242723

Group type: EXPERIMENTAL
Intervention: Proactive outpatient care based on Comprehensive Geriatric Assessment
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1212
Study: 34755627

Group type: EXPERIMENTAL
Intervention: Maralixibat 380 μg/kg once per day for 18 weeks, followed by random assignment to continue maralixibat or receive placebo for 4 weeks.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Maralixibat continued treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Maralixibat continued treatment until week 204
Number of subjects: 31
Study: 34622766

Group type: EXPERIMENTAL
Intervention: Vaccine group
Number of subjects: 119110

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 119110
Study: 33483613

Group type: EXPERIMENTAL
Intervention: IM 400 mg
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: IM 600 mg
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: IM 400 mg + cytarabine (AraC)
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: IM 400 mg + pegylated interferon alpha2a (PegIFN‐α2a)
Number of subjects: 787
Study: 33618023

Group type: EXPERIMENTAL
Intervention: Ustekinumab every 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ustekinumab every 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ustekinumab (LTE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33640516

Group type: EXPERIMENTAL
Intervention: SRAE with 500-700 μm tris-acryl gelatin microspheres
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SRAE with 700-900 μm tris-acryl gelatin microspheres
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SRAE with 900-1,200 μm tris-acryl gelatin microspheres
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SRAE with tris-acryl gelatin microspheres (all groups)
Number of subjects: 42
Study: 35472008

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33487305

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry with FFP2 mask
Number of subjects: 10

Group type: COMPARATOR
Intervention: Indirect calorimetry without FFP2 mask
Number of subjects: 10
Study: 36002798

Group type: EXPERIMENTAL
Intervention: BF text messages plus app
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: BF text messages, app and physician-moderated private Facebook group
Number of subjects: 346

Group type: COMPARATOR
Intervention: Attention control group (injury prevention texts)
Number of subjects: 346
Study: 34494323

Group type: EXPERIMENTAL
Intervention: 40 g soy flour (whole soy group)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 40 g low-fat milk powder + 63 mg daidzein (daidzein group)
Number of subjects: 270

Group type: COMPARATOR
Intervention: 40 g low-fat milk powder (placebo)
Number of subjects: 270
Study: 35468621

Group type: EXPERIMENTAL
Intervention: F16IL2 (10 × 10^6 to 20 × 10^6 IU IV; days 1, 8, 15, and 22 of each 28‐day cycle) + BI 836858 (10-40 mg IV, 2 days after each F16IL2 infusion)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: F16IL2 + BI 836858
Number of subjects: 15
Study: 32071262

Group type: EXPERIMENTAL
Intervention: Higher short sleep duration score
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Higher late sleep score
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Habitual late sleep in high risk children
Number of subjects: 107
Study: 35283262

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drug for heart failure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33576005

Group type: EXPERIMENTAL
Intervention: Exposure to scented products (leave-on products and specific scented product subgroups)
Number of subjects: 3119

Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 3119

Group type: EXPERIMENTAL
Intervention: Participants age 40 years and older
Number of subjects: 3119

Group type: EXPERIMENTAL
Intervention: Sensitive skin
Number of subjects: 3119

Group type: EXPERIMENTAL
Intervention: Aggregate exposure to scented leave-on products
Number of subjects: 3119
Study: 36036611

Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 340
Study: 34936264

Group type: EXPERIMENTAL
Intervention: Nape cluster acupuncture
Number of subjects: 120
Study: 34378458

Group type: EXPERIMENTAL
Intervention: Implantable defibrillators
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: Sigmoidal model
Number of subjects: 2521

Group type: COMPARATOR
Intervention: Linear model
Number of subjects: 2521
Study: 33450736

Group type: EXPERIMENTAL
Intervention: SAFIRE grade I
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: SAFIRE grade II
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: SAFIRE grade III
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: SAFIRE grade IV
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: SAFIRE grade V
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: SAFIRE grade IV or V
Number of subjects: 405
Study: 34879326

Group type: EXPERIMENTAL
Intervention: %TTD macro program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: %TUDD macro program
Number of subjects: 0
Study: 32072866

Group type: EXPERIMENTAL
Intervention: FamTechCare video support
Number of subjects: 84

Group type: COMPARATOR
Intervention: Telephone support (control)
Number of subjects: 84
Study: 34952574

Group type: EXPERIMENTAL
Intervention: 3D printing personalized percutaneous puncture guide access plate for PCNL
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard USG guide PCNL
Number of subjects: 22
Study: 32614264

Group type: EXPERIMENTAL
Intervention: OSG+V (online synchronous chat group with AYA-created film)
Number of subjects: 34

Group type: COMPARATOR
Intervention: OSG+E (online synchronous chat group plus education)
Number of subjects: 34
Study: 34327538

Group type: EXPERIMENTAL
Intervention: NIO automatic intraosseous device
Number of subjects: 60

Group type: COMPARATOR
Intervention: TALON manual intraosseous device
Number of subjects: 60
Study: 34658904

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR) during exercise test
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard exercise test (without VR)
Number of subjects: 70
Study: 35552107

Group type: COMPARATOR
Intervention: WT+RUPP
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: KO+RUPP
Number of subjects: 24
Study: 32347934

Group type: EXPERIMENTAL
Intervention: Olaparib 150 mg (3 days/week) with TMZ 75 mg/m2 daily for 42 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 39
Study: 36227220

Group type: EXPERIMENTAL
Intervention: Tailored nutritional dietary rehabilitation plan including dietary supplements
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dietary advice only
Number of subjects: 100
Study: 34916320

Group type: COMPARATOR
Intervention: Conventional regimen of doxorubicin and cisplatin
Number of subjects: 377

Group type: COMPARATOR
Intervention: Dose-intense regimen of doxorubicin and cisplatin
Number of subjects: 377
Study: 34711482

Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion (RPE) using hyrax-type appliances
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nontreated control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion (RPE)
Number of subjects: 80
Study: 32865258

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) programme
Number of subjects: 58

Group type: COMPARATOR
Intervention: Theoretical training session
Number of subjects: 58
Study: 36327399

Group type: EXPERIMENTAL
Intervention: Salicylic acid via foliar spraying
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Salicylic acid via irrigation
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (without application of salicylic acid)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Salicylic acid via spraying and irrigation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Salicylic acid via spraying
Number of subjects: 5
Study: 32851713

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy
Number of subjects: 143

Group type: COMPARATOR
Intervention: JJ stent
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 143